Skip to main content
SpringerLink
Log in

Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Aims

Data from experimental studies suggest that the f current-inhibitor ivabradine may reduce oxidative stress and improve endothelial function. We aimed to evaluate the effect of ivabradine on endothelial function in patients with coronary artery disease (CAD) after complete revascularization with percutaneous coronary angioplasty (PCI).

Methods and results

At least 30 days after PCI, 70 patients were randomized (T0) to receive ivabradine 5 mg twice daily (ivabradine group, n = 36) or to continue with standard medical therapy (control group, n = 34). After 4 weeks (T1), ivabradine dose was adjusted up to 7.5 mg twice daily in patients with heart rate (HR) at rest >60 bpm, and thereafter continued for additional 4 weeks (T2). At all timings, brachial artery reactivity was assessed by flow-mediated dilatation (FMD) and nitroglycerin-mediated dilatation (NMD). No significant differences were observed at T0 between ivabradine and control groups in terms of HR (68.0 ± 6.4 vs. 67.6 ± 6.4 bpm; p = 0.803), FMD (8.7 ± 4.9 vs. 8.0 ± 5.5 %; p = 0.577) and NMD (12.7 ± 6.7 vs. 13.3 ± 6.2 %; p = 0.715). Over the study period, a significant reduction of HR (65.2 ± 5.9 bpm at T1, 62.2 ± 5.7 bpm at T2; p < 0.001), and improvement of FMD (12.2 ± 6.2 % at T1, 15.0 ± 7.7 % at T2; p < 0.001) and NMD (16.6 ± 10.4 % at T1, 17.7 ± 10.8 at T2; p < 0.001) were observed in the ivabradine group, while no significant changes were observed in the control group. In the ivabradine group, a moderate negative correlation was observed between the HR variation and FMD variation from T1 to T3 (r = −0.448; p = 0.006).

Conclusions

In patients with CAD undergoing complete revascularization with PCI, addition of ivabradine to the standard medical therapy produces a significant improvement in endothelial function. This effect seems to be related to HR reduction.

ClinicalTrials.gov number, NCT02681978.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kannel WB, Kannel C, Paffenbarger RSJ, Cupples LA (1987) Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 113:1489–1494

    Article  CAS  PubMed  Google Scholar 

  2. Diaz A, Bourassa MG, Guertin MC, Tardif JC (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26:967–974

    Article  PubMed  Google Scholar 

  3. Kolloch R, Legler UF, Champion A et al (2008) Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 29:1327–1334

    Article  PubMed  PubMed Central  Google Scholar 

  4. Custodis F, Schirmer SH, Baumhakel M, Heusch G, Bohm M, Laufs U (2010) Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 56:1973–1983

    Article  CAS  PubMed  Google Scholar 

  5. Lang CC, Gupta S, Kalra P et al (2010) Elevated heart rate and cardiovascular outcomes in patients with coronary artery disease: clinical evidence and pathophysiological mechanisms. Atherosclerosis 212:1–8

    Article  CAS  PubMed  Google Scholar 

  6. Fratta Pasini A, Garbin U, Nava MC et al (2005) Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 23:589–596

    Article  PubMed  Google Scholar 

  7. Ghiadoni L, Magagna A, Versari D et al (2003) Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 41:1281–1286

    Article  CAS  PubMed  Google Scholar 

  8. Heffernan KS, Suryadevara R, Patvardhan EA, Mooney P, Karas RH, Kuvin JT (2011) Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. Clin Cardiol 34:39–44

    Article  PubMed  Google Scholar 

  9. Jochmann N, Schroter F, Knebel F et al (2014) Effect of ivabradine-induced heart rate reduction on flow-mediated dilation measured with high-sensitivity ultrasound in patients with stable coronary heart disease. Cardiovasc Ultrasound 12:5

    Article  PubMed  PubMed Central  Google Scholar 

  10. Nerla R, Di Franco A, Milo M et al (2012) Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients. Heart 98:1812–1816

    Article  CAS  PubMed  Google Scholar 

  11. DiFrancesco D, Camm JA (2004) Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64:1757–1765

    Article  CAS  PubMed  Google Scholar 

  12. Fischer-Rasokat U, Honold J, Lochmann D et al (2014) Ivabradine therapy to unmask heart rate-independent effects of β-blockers on pulse wave reflections. Clin Res Cardiol 103:487–494

    Article  CAS  PubMed  Google Scholar 

  13. Fischer-Rasokat U, Honold J, Lochmann D et al (2016) β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index. Clin Res Cardiol 105:527–534

    Article  CAS  PubMed  Google Scholar 

  14. Kröller-Schön S, Schulz E, Wenzel P et al (2011) Differential effects of heart rate reduction with ivabradine in two models of endothelial dysfunction and oxidative stress. Basic Res Cardiol 106:1147–1158

    Article  PubMed  Google Scholar 

  15. Custodis F, Baumhakel M, Schlimmer N et al (2008) Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117:2377–2387

    Article  CAS  PubMed  Google Scholar 

  16. Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, Tardif JC (2008) Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol 154:749–757

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Patti G, Pasceri V, Melfi R et al (2005) Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation 111:70–75

    Article  PubMed  Google Scholar 

  18. Levine HJ (1997) Rest heart rate and life expectancy. J Am Coll Cardiol 30:1104–1106

    Article  CAS  PubMed  Google Scholar 

  19. Boudoulas KD, Borer JS, Boudoulas H (2015) Heart rate, life expectancy and the cardiovascular system: therapeutic considerations. Cardiology 132:199–212

    Article  PubMed  Google Scholar 

  20. Custodis F, Roggenbuck U, Lehmann N et al (2016) Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population. Clin Res Cardiol 105:601–612

    Article  PubMed  Google Scholar 

  21. Heidland UE, Strauer BE (2001) Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104:1477–1482

    Article  CAS  PubMed  Google Scholar 

  22. Huikuri HV, Jokinen V, Syvanne M et al (1999) Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 19:1979–1985

    Article  CAS  PubMed  Google Scholar 

  23. Schirmer SH, Degen A, Baumhakel M et al (2012) Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J 33:1223–1231

    Article  CAS  PubMed  Google Scholar 

  24. Villano A, Di Franco A, Nerla R et al (2013) Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol 112:8–13

    Article  CAS  PubMed  Google Scholar 

  25. Akcakoyun M, Kargin R, Tanalp AC et al (2008) Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events and restenosis in patients undergoing coronary stent implantation: a prospective study. Coron Artery Dis 19:337–343

    Article  PubMed  Google Scholar 

  26. Kitta Y, Nakamura T, Kodama Y et al (2005) Endothelial vasomotor dysfunction in the brachial artery is associated with late in-stent coronary restenosis. J Am Coll Cardiol 46:648–655

    Article  PubMed  Google Scholar 

  27. Matsuzawa Y, Sugiyama S, Sumida H et al (2013) Peripheral endothelial function and cardiovascular events in high-risk patients. J Am Heart Assoc 2:e000426

    Article  PubMed  PubMed Central  Google Scholar 

  28. Tabata N, Hokimoto S, Akasaka T et al (2015) Differential impact of peripheral endothelial dysfunction on subsequent cardiovascular events following percutaneous coronary intervention between chronic kidney disease (CKD) and non-CKD patients. Heart Vessels 31:1038–1044

    Article  PubMed  Google Scholar 

  29. Kitta Y, Obata JE, Nakamura T et al (2009) Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 53:323–330

    Article  PubMed  Google Scholar 

  30. Montalescot G, Sechtem U, Achenbach S et al (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949–3003

    Article  PubMed  Google Scholar 

  31. Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:807–816

    Article  CAS  PubMed  Google Scholar 

  32. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R (2014) Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371:1091–1099

    Article  PubMed  Google Scholar 

  33. Swedberg K, Komajda M, Bohm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Via Álvaro del Portillo, 200, 00128, Rome, Italy

    Fabio Mangiacapra, Iginio Colaiori, Elisabetta Ricottini, Francesco Balducci, Antonio Creta, Chiara Demartini & Germano Di Sciascio

  2. Unit of Drug Science, Department of Medicine, Campus Bio-Medico University, Rome, Italy

    Giorgio Minotti

Authors
  1. Fabio Mangiacapra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iginio Colaiori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elisabetta Ricottini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Balducci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Antonio Creta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chiara Demartini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giorgio Minotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Germano Di Sciascio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabio Mangiacapra.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mangiacapra, F., Colaiori, I., Ricottini, E. et al. Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. Clin Res Cardiol 106, 69–75 (2017). https://doi.org/10.1007/s00392-016-1024-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-016-1024-7

Keywords

Search

Navigation